physical association with TGFb pathway components has not been reported. Therefore, we anchored our unsupervised clustering on PAK1 and sorted prey SOMs to identify similar profiles. The resulting cluster (Fig.  3C ) contained known PAK1-binding proteins, such as the PAK-interacting Cdc42 exchange factor, ARHGEF6 (a-PIX), and oxidative stress-response kinase-1 (OSR1) (19, 21) , as well as Occludin (OCLN), a tight junction accessory protein that is associated with the cell polarity network (22) (fig. S7A ). Therefore, we validated the interaction of a number of these proteins with TGFb receptors (fig. S6) (10) , which included validating interactions between endogenous TbRI and both PAK1 and OCLN. Further, although physical links reported between PAK1 and Polarity-OCLN networks are few ( fig. S7A ), analysis of LUMIER data revealed substantial connections between the TGFb pathway and both networks ( fig. S7B ).
TGFb induces dissolution of tight junctions and acquisition of a mesenchymal phenotype in breast epithelial culture models (23, 24) . Therefore, we examined the OCLNTGFb receptor complex in normal mammary gland epithelial cells (NMuMG). Interaction of endogenous OCLN with endogenous TbRI was not modulated by TGFb (Fig. 4A) , whereas its association with the TGFb type II receptor increased in a ligand-dependent manner ( Fig. 4A ) and OCLN interacted with cell surface affinity-labeled TGFb receptor complexes (Fig. 4B ). Using LUMIER, we mapped the TbRI-interacting region of OCLN to extracellular loop 2 (L2) (Fig.  4C ). TbRI is localized to tight junctions in polarized NMuMG cells (25) . To determine whether OCLN might contribute to regulating TbRI localization, we used OCLN(DL2) as a dominant negative. Confocal microscopy in polarized NMuMG cells revealed that the WT, as well as the extracellular loop 1 (DL1) and DL2 mutants of OCLN, localized with ZO-1 on the apical aspect of the cell in tight junctions (Fig. 4D) . Localization of Myctagged TbRI in tight junctions was unaffected by WT OCLN or OCLN(DL1), both of which interacted with TbRI. In contrast, OCLN(DL2) caused mislocalization of TbRI across the surface of the cell (Fig. 4D) . Moreover, when we examined the epithelial-to-mesenchymal transition (EMT) in these cells, 40% of OCLN(DL2)-expressing cells exhibited retained tight junctions after TGFb treatment, compared with only 10% of control cells ( Fig. 4E) (11) . In contrast, none of the OCLN mutants affected TGFb-dependent induction of a Smad-responsive reporter gene ( fig. S8 ). Thus, OCLN regulates TbRI localization to tight junctions, and this is important for efficient TGFb-dependent dissolution of tight junctions during EMT. This suggests that targets of the receptor complex localized to tight junctions are involved in EMT, and in a separate study, we show that Par6, a key regulatory component of tight junctions, is an important downstream effector of this pathway (25 
*
The steroid hormone estrogen regulates many functionally unrelated processes in numerous tissues. Although it is traditionally thought to control transcriptional activation through the classical nuclear estrogen receptors, it also initiates many rapid nongenomic signaling events. We found that of all G protein-coupled receptors characterized to date, GPR30 is uniquely localized to the endoplasmic reticulum, where it specifically binds estrogen and fluorescent estrogen derivatives. Activating GPR30 by estrogen resulted in intracellular calcium mobilization and synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. Thus, GPR30 represents an intracellular transmembrane estrogen receptor that may contribute to normal estrogen physiology as well as pathophysiology.
Estrogen (17b-estradiol, E2) represents one of a family of steroid hormones that act through soluble intracellular receptors. Once activated, these receptors translocate to the nucleus, where they function as liganddependent transcription factors (1, 2). This mode of action of two such estrogen-binding receptors, ERa and ERb, is reasonably well understood (3, 4) . However, the existence of functional ERs associated with the plasma membrane has been debated (5) . It has been suggested that such membrane receptors me-diate the rapid nongenomic signaling events widely observed following stimulation of cells and tissues with estrogen, including the generation of the second messengers Ca 2þ and nitric oxide as well as the activation of receptor tyrosine kinase and proteinlipid kinase pathways (1, (6) (7) (8) (9) . The cellular consequences can include adhesion, migration, survival, proliferation, and cancer. Novel receptors and novel forms of ER have been postulated to mediate many of these signal transduction events (8) . G protein-coupled receptors (GPCRs) represent the largest class of signaling molecules in the human genome (10) . They are heptahelical transmembrane proteins (11) expressed on the cell surface, where the binding of agonists (12) initiates activation of heterotrimeric guanine nucleotide-binding proteins (G proteins) and downstream regulatory proteins (13) and effectors (14) . It has been suggested that rapid nongenomic estrogenmediated signaling may involve the GPCR, GPR30 (15) based on correlations of receptor expression with estrogen-mediated Erk activation (16) , and cellular estrogen binding (17) . Despite these assertions that a 7-transmembrane GPCR may be involved in estrogen-dependent signaling, no mechanisms have been demonstrated to explain the function of GPR30 in these processes.
To define the role of GPR30 in estrogenmediated cell activation, we expressed GPR30 as a fusion protein with green fluorescent protein (GFP) in COS7 (monkey kidney fibroblast) cells (18) . To examine the cellular localization of the receptor, GPR30-GFP was expressed with the b 2 -adrenergic receptor (b 2 -AR), a GPCR (Fig. 1A) . Confocal fluorescence microscopy revealed that the b 2 -AR was localized to the plasma membrane, whereas GPR30-GFP was observed in an intracellular tubuloreticular network, including the nuclear envelope in some cases. To identify the specific subcellular localization of GPR30-GFP, we performed localization studies with markers for mitochondria, the endoplasmic reticulum, the Golgi apparatus, and the actin cytoskeleton. Staining of GPR30-GFP-expressing cells with either an antibody to KDEL (an endoplasmic reticulum retrieval sequence) or er-YFP (a subcellular localization marker targeting YFP to the endoplasmic reticulum using calreticulin and KDEL sequences) yielded nearly complete colocalization with GPR30-GFP. Coexpression of TGN38-GFP (a Golgi-resident protein) with GPR30-monomeric red fluorescent protein1 (mRFP1) also demonstrated co- localization. No colocalization was observed between GPR30-GFP and mitochondria or the actin cytoskeleton.
Because heterologous expression of GPCRs can result in retention of the receptor in the endoplasmic reticulum and Golgi, we examine the expression of endogenous GPR30. Antibodies were generated against the predicted N-and C-terminal peptides of GPR30, both of which recognized GPR30-GFP expressed in COS7 cells (Fig. 1B) . The C-terminal antibody did not detect an amino-terminally epitopetagged truncated form of GPR30 that lacked the C-terminal 24 amino acids (Fig. 1C) , although it was still expressed in the endoplasmic reticulum. Both the C-terminally truncated form of GPR30 and endogenous GPR30 were expressed with the same localization pattern (Fig. 1D) . Furthermore, this C-terminal antibody identified endogenous GPR30 in a number of cancer cell lines [breast cancers MCF7, SKBr3, and MDA-MB231; juxtaglomerular epithelioid granular (JEG) choriocarcinoma; and Hec50 uterine carcinoma] in a localization pattern identical to that observed for GPR30-GFP in transfected COS7 cells (Fig. 1E) . MDA-MB-231 breast cancer cells exhibited somewhat lower expression of GPR30, whereas HTR8 normal extravillous trophoblasts, Ishikawa H cells (differentiated hormone-responsive uterine cells), and COS7 cells exhibited little to no expression. Whereas the aggressive cancer cell lines (JEG and Hec50) expressed high levels of GPR30, their associated normal cell lines (HTR8 and H, respectively) showed little to no expression of GPR30. JEG cells expressed a level of GPR30 at least 10 times as high as that of HTR8 cells (Fig. 1F) , quantitatively confirming the results observed by confocal microscopy (Fig. 1E) . Taken together, these results demonstrate that GPR30 is a 7-transmembrane receptor localized predominantly in the endoplasmic reticulum.
Intracellular localization has important implications for the function of a GPCR. Any natural ligand for the receptor must be membrane permeable and, furthermore, signal transduction molecules (e.g., G proteins and kinases) accessible to the receptor on internal membranes may be very different from those available to a receptor on the plasma membrane. To date, a cognate stoichiometric ligand for GPR30 has not been firmly established. Because GPR30-positive cells were responsive to estrogens, we determined whether GPR30 could directly bind to estrogen. We developed a family of fluorescent estrogens based on 17a-E4-aminomethyl-phenylethynyl^-estra-1, 3,5(10)-triene-3, 17b-diol, which contains a single reactive amine at the distal end of a linker that is attached to the 17a position of 17b-estradiol (19) . This estrogen derivative was conjugated to the N-hydroxysuccinimidyl ester forms of various Alexa dyes (Fig. 2A) . The resulting products, E2-Alexa 546 and E2-Alexa 633 were purified by reverse-phase highperformance liquid chromatography. To test the binding ability of these fluorescent estrogens, we expressed ERa-GFP in COS7 cells and stained the transfected cells with E2-Alexa 633. Unpermeabilized cells did not stain with E2-Alexa 633 (or 546) because of the impermeability of the charged Alexa dyes (Fig. 2B) . However, transfected cells permeabilized with saponin demonstrated binding that coincided 
the binding of the E2-Alexa derivatives. Confocal fluorescence microscopy revealed that E2-Alexa 546 staining also colocalized nearly completely with GPR30-GFP expression in the endoplasmic reticulum and Golgi and that the binding could be competed by excess 17b-estradiol (Fig. 2C) . No binding of the E2-Alexa 546 to the plasma membrane was observed, confirming the absence of GPR30 at the plasma membrane. We next stained the same panel of cell lines used in Fig. 1E with E2-Alexa 546 (Fig. 2D) . In each cell type, the intensity and pattern of staining of the fluorescent estrogen was consistent with the level and pattern of GPR30 protein expression (Fig. 1E) . To characterize the binding properties of the novel fluorescent estrogens further, we compared the level of E2-Alexa 633 binding to the expression level of ERa-GFP, ERb-GFP, and GPR30-GFP in transfected COS7 cells, using b 2 -AR-GFP-expressing cells as a control. A direct linear correlation was observed, which supports direct binding of estrogen by GPR30 (Fig. 2E) . Competition binding assays of E2-Alexa 633 binding with 17b-estradiol demonstrated a K i for 17b-estradiol of approximately 6.6 nM for GPR30 (Fig. 2F ). These results demonstrate that a classic GPCR superfamily member directly binds a sex steroid hormone and that GPR30 is an estrogen-binding receptor.
To determine whether GPR30 mediates rapid nongenomic signaling, we expressed GPR30-GFP and ERa-GFP in COS7 cells and then loaded the cells with the Ca 2þ indicator Indo1-AM. Whereas 17b-estradiol stimulation of mock-transfected cells yielded only a negligible mobilization of Ca 2þ (Fig. 3B) , stimulation of either ERa-GFP-expressing or GPR30-GFPexpressing cells resulted in a mobilization of intracellular calcium similar in magnitude to the response evoked by stimulation of purinergic receptors with adenosine triphosphate (Fig. 3,  A and B) . In contrast, an inactive isomer of estrogen, 17a-estradiol, did not induce a calcium response via either receptor when used at concentrations 1000 times as high as that of 17b-estradiol. Estrogen-mediated mobilization of intracellular Ca 2þ was observed at 17b-estradiol concentrations below 0.1 nM, with an EC 50 value of approximately 0.5 nM (Fig. 3C) . These results suggest that the selectivity of GPR30 toward estrogen is similar to that of the ER. This is not unexpected, because the two hydroxyl groups of estrogen represent natural sites for ligand recognition and binding (20) .
As numerous estrogen-mediated rapid signaling events are sensitive to pertussis toxin, which implies the involvement of Gi/o proteins, we determined whether ERa and GPR30 stimulated calcium mobilization in this pathway. Whereas pertussis toxin completely blocked ERa-mediated calcium mobilization (Fig. 3A) , inhibition of GPR30-mediated calcium mobilization was only partial (È50%) (Fig. 3B) . Furthermore, because activation of mitogenactivated protein kinase signaling by GPR30 was suggested to occur through epidermal growth factor receptor (EGFR) transactivation (16) and GPCR-mediated calcium mobilization is mediated by phospholipase C (PLC)-dependent inositol 1,4,5-trisphosphate production, we assessed whether either of these pathways is involved in estrogen-stimulated calcium mobilization by ERa and GPR30. GPR30-mediated calcium mobilization was completely blocked by the EGFR inhibitor AG1478 but not by the PLC inhibitor U73122, whereas the ERa response was completely blocked by the PLC inhibitor but not substantially by the EGFR inhibitor. These results suggest that ER-and GPR30-initiated calcium mobilization are mediated by divergent signaling pathways.
Estrogen stimulates numerous intracellular kinase signaling pathways (8) , including the phosphoinositide 3-kinase (PI3K)-Akt pathway, which leads to proliferative signaling. Such estrogen-dependent signaling has been observed even in apparently ER-negative cell lines (21) . Activation of PI3K leads to the membranelocalized accumulation of phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn acts to recruit Akt to the membrane through its pleckstrin homology (PH) domain. Molecular fusion of the isolated PH domain of Akt to fluorescent proteins has been widely used to assess PIP3 accumulation and localization (22) . To investigate estrogen-mediated activation of PI3K, we transfected COS7 cells with a PH domain fused to monomeric red fluorescent protein1 (PH-mRFP1) and either ERa-GFP or GPR30-GFP. In unstimulated cells, the PH-mRFP1 reporter was localized primarily throughout the cytoplasm, with slightly higher concentrations found in the nucleus of some cells (Fig. 3, D and E) . Upon stimulation with 17b-estradiol, ER-GFP-expressing cells displayed an almost complete translocation of PH-mRFP1 to the nucleus (Fig. 3D) . A similar response was seen with GPR30-GFP-expressing cells (Fig. 3E) , although the translocation on average was not as complete. Inhibition of PI3K by LY294002 prevented the translocation of the PH-mRFP1 to the nucleus by both receptors. Although tamoxifen Ea selective estrogen receptor modulator (SERM)^induced calcium mobilization in both ERa-GFP-transfected and GPR30-GFP-transfected cells (23) , it induced relocalization of the PH-mRFP1 only in GPR30-GFP-expressing cells. Furthermore, although PH-mRFP1 translocated to the nucleus, it also translocated to membranes of the endoplasmic reticulum containing GPR30-GFP. This result suggests that tamoxifen acts differentially on GPR30-and ER-mediated nuclear signal transduction and that tamoxifen activates GPR30 in a spatially different manner from estrogen. Accumulation of PIP3 by either receptor was not inhibited by pertussis toxin, indicating that ER-mediated calcium mobilization and PI3K activation occur by distinct mechanisms. PIP3 generation by GPR30, but not by ER, requires EGFR activation, indi-
We examined whether activation of PI3K by intracellular GPR30 also occurs in a breast cancer cell line (SKBr3) expressing endogenous GPR30 but lacking ERa and ERb. PHmRFP1-transfected SKBr3 cells responded to 17b-estradiol and tamoxifen stimulation with nuclear accumulation of PIP3, as demonstrated by translocation of the PH-mRFP1 (Fig. 4A) . Unstimulated cells displayed PH-mRFP1 in the plasma membrane and cytoplasm. SKBr3 cells exhibit constitutive activation of ErbB2 signaling (24) , which presumably induces PI3K-dependent plasma membrane localization of PH-mRFP1 in unstimulated cells. This is supported by the cytosolic localization of the PH-mRFP1 reporter upon treatment of unstimulated cells with PI3K and EGFR inhibitors (23) . These same inhibitors also prevented the nuclear accumulation of PH-mRFP1 in estrogen-stimulated cells, which demonstrates that the estrogen-mediated signaling in SKBr3 cells occurs through the EGFR and PI3K, as demonstrated for GPR30 in COS7 cells. To demonstrate that GPR30 alone was responsible for the PI3K signaling observed in SKBr3 cells, we employed antisense-mediated depletion of endogenous GPR30. Expression of GPR30 antisense resulted in a marked reduction in GPR30 expression, whereas expression of b 2 -AR antisense did not affect GPR30 expression (Fig. 4B) . Expression of GPR30 antisense also reduced binding of E2-Alexa 546 to transfected SKBr3 cells (Fig. 4, C and D) . To determine whether GPR30 depletion would abrogate estrogen-mediated PI3K activation, we coexpressed antisense vectors (either GPR30 or b 2 -AR), PH-mRFP1 (to assess PIP3 synthesis and localization), and GFP (to mark transfected cells). 17b-estradiol stimulation of GPR30 antisense-expressing cells did not cause PH-mRFP1 translocation (Fig. 4E) , which demonstrates that the GPR30 represents the sole estrogen-binding and functionally responsive estrogen receptor in SKBr3 cells.
Mechanisms of estrogen-mediated cellular activation have become increasingly complex. Rapid nongenomic ER-mediated signaling has been proposed to occur through distinct cellular localization of the classical ER, through classical heterotrimeric G proteins, and through many of the effectors traditionally associated with growth factors and GPCRs. Estrogen is one of the small number of membrane-permeable physiological ligands, consistent with the lack of requirement for GPR30 to be expressed on the cell surface. In some cell types, GPR30 represents the sole estrogen-responsive receptor. In direct comparison with ER-mediated signaling, GPR30-mediated signaling occurs via a distinct signal transduction pathway, and the effects of estrogen through this receptor may likely be a consequence of its intracellular localization.
Differential Lysosomal Proteolysis in Antigen-Presenting Cells Determines Antigen Fate
Lélia Delamarre, Margit Pack, Henry Chang, Ira Mellman,* E. Sergio Trombetta* Antigen-presenting cells (APCs) internalize antigens and present antigenderived peptides to T cells. Although APCs have been thought to exhibit a well-developed capacity for lysosomal proteolysis, here we found that they can exhibit two distinct strategies upon antigen encounter. Whereas macrophages contained high levels of lysosomal proteases and rapidly degraded internalized proteins, dendritic cells (DCs) and B lymphocytes were proteasepoor, resulting in a limited capacity for lysosomal degradation. Consistent with these findings, DCs in vivo degraded internalized antigens slowly and thus retained antigen in lymphoid organs for extended periods. Limited lysosomal proteolysis also favored antigen presentation. These results help explain why DCs are able to efficiently accumulate, process, and disseminate antigens and microbes systemically for purposes of tolerance and immunity.
Whereas antibodies typically recognize intact antigens, T lymphocytes recognize proteins as short peptides presented by the major histocompatibility complex (MHC) molecules to induce antigen-specific responses to foreign proteins and tolerance to self proteins. Peptides generated by lysosomal proteases bind to MHC class II molecules, which are then displayed at the cell surface of a limited subset of antigenpresenting cells (APCs) including macrophages (MKs), dendritic cells (DCs), and B cells. Due in part to their marked endocytic and phagocytic capacity, MKs were long considered the prototypical APCs. It is now well established, however, that DCs are also highly endocytic and even more potent APCs (1-3) . Much of what is known about antigen processing is derived from studies of cultured cells. To evaluate the relative contribution of lysosomal proteases to antigen presentation in vivo, we analyzed by immunofluorescence microscopy the expression of individual proteases in situ in secondary lymphoid organs of mice. Cathepsin S (cat S), considered to be selectively expressed by APCs such as B cells and DCs, was expressed most abundantly in the MK-rich marginal zone of the spleen (SIGN-R1-positive). Under the same staining conditions, cat S was barely detected in B cell areas or in T cell areas where the majority of DCs reside (Fig. 1A) . The same pattern of expression was found for an array of other lysosomal proteases Ecat L, K, and asparagine endopeptidase (AEP) (Fig. 1A) and cat B, D, E, H, and O ( fig. S1 )^in the spleen, whether assayed by immunofluorescence on tissue sections (Fig. 1A) , on dissociated spleen cells ( fig. S2 ), or by immunoblot (Fig. 1B) . Similarly, lysosomal proteases in lymph nodes were also greatly enriched in SIGN-R1-positive MK regions but present at low amounts in B and T cell zones where the majority of MHC class II-high cells reside (Fig. 1A) . Thus, in vivo APCs differ broadly in their capacities for antigen degradation, with cells rich in MHC class II (B cells and DCs) containing substantially lower amounts of lysosomal proteases than MKs.
The marked differences in lysosomal protease content between DCs and MKs observed in vivo was recapitulated during differentiation of bone marrow precursors into the MK lineage Eby macrophage-colony stimulating factor (CSF)^or the DC lineage
